Beckman Coulter Diagnostics has secured the US Food and Drug Adminisration (FDA) clearance for the commercial launch of its new DxC 700 AU chemistry analyser.
The new system combines the design of the DxC analyser with the throughput capabilities of the AU analyser into one standardised platform for mid- to high-volume clinical laboratories.
Beckman Coulter Diagnostics chemistry and immunoassay senior vice-president John Blackwood said: "With the DxC 700 AU analyser, Beckman Coulter Diagnostics has created a truly innovative product by combining two time-proven technologies of DxC and AU.
"Additionally, by gaining further input from the clinical laboratory professionals, who are under pressure daily to produce faster results and manage resources more efficiently, additional features and benefits were identified and designed into the product."
The DxC 700 AU chemistry analyser features a new and intuitive user-interface, which decreases the number of test-processing steps by 30%.
The system enables operators to spend more time on producing the quality results that allow better decision-making for patient care.
The analyser is also claimed to use less consumables, resulting in the decrease of total cost of ownership.
It utilises concentrated reagents, long-lasting ion-selective electrodes (ISEs) and non-disposable cuvettes to aid laboratory specialists in achieving financial goals and managing resources.
The new analyser is a part of the firm's total laboratory solution, which includes the Power Link system, the Power Express, Remisol and Command Central.
Beckman Coulter plans to further expand the availability of the new device to other countries in the coming months.
Image: DxC 700 AU chemistry analyser. Photo: courtesy of Beckman Coulter Diagnostics.